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Neurodegenerative diseases are among the most serious health problems affecting millions of
people worldwide, and their incidence is dramatically growing together with increased lifespan [1].
These diseases are a heterogeneous group of chronic, progressive disorders characterized by the
gradual loss of neurons in the central nervous system, which leads to deficits in specific brain functions.
The most common neurodegenerative diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis, multiple sclerosis, and Huntington’s disease. While the etiology of most
neurodegenerative diseases is mainly unknown, it is largely recognized that these disorders share
common molecular and cellular characteristics that contribute to their progression. These include
oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, dysregulation of calcium
homeostasis, and inflammation [2–5]. There are currently no therapeutic approaches to cure or even
halt the progression of these disorders, and existing treatments remain largely palliative. In this
context, natural products, because of their broad spectrum of pharmacological and biological activities,
are considered promising alternatives for the treatment of neurodegeneration as they might play a role
in drug development and discovery. A number of studies showed health-promoting properties in the
use of natural products as potential therapeutics for neurodegeneration [6–8]. Natural compounds
have been reported to possess different biological activities, including antioxidant, anti-inflammatory,
and antiapoptotic effects [9,10]. Moreover, natural compounds have been recently shown to counteract
protein misfolding and to modulate autophagy and proteasome activity [11,12].
The papers published as part of this Special Issue deal with two different forms of natural products:
extracts and isolated compounds. The study of the bioactivity of the extracts is extremely important as
in vivo natural compounds are usually obtained through the diet as a complex mixture. The importance
of extracts is further supported by the fact that many studies have demonstrated the synergistic effect
of the combination of different natural products [13]. On the other hand, the investigation of the
activity of specifically isolated natural products can be also important to understand their cellular and
molecular mechanisms and to define what are the specific bioactive components in extracts or foods.
Research conducted by Sabti M. and colleagues [14] elucidated the molecular mechanisms
underlying the relaxant and anxiolytic properties of Lippia citriodora (VEE) and verbascoside (Vs),
a phenypropanoid glycoside. Lippia citriodora is a plant from the Verbenaceae family and is cultivated
in North Africa, Southern Europe and the Middle East. In this study both an in vivo mouse model of
anxiety and depression and the in vitro SH-SY5Y cell line were employed. In particular the authors
evidenced a relaxation effect of high doses of VEE associated with the regulation of genes playing
key roles in calcium homeostasis (calcium channels), cyclic AMP (cAMP) production and energy
metabolism. Low doses of VEE and Vs showed an antidepressant-like effect by enhancing brain-derived
neurotrophic factor (BDNF), noradrenalin, serotonin and dopamine expressions. These results were
further confirmed in vitro as both VEE and Vs enhanced cell viability, mitochondrial activity and
calcium uptake in SH-SY5Y cells.
In their manuscript, Lee Y.G. et al. [15] isolated four flavonols, three flavones, four flavanonols,
and one flavanone from a Chionanthus retusus extract, a deciduous tree of the Oleaceae family mainly
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cultivated in Korea, Japan and China. Eight of these flavonoids demonstrated to be effective in
counteracting inflammation by inhibiting nitric oxide (NO) production in RAW 264.7 cells activated by
lipopolysaccharide. In addition, these flavonoids showed a neuroprotective activity counteracting
glutamate-induced cell toxicity increasing heme oxygenase 1 (HO-1) protein expression in mouse
hippocampal HT22 cells.
Similarly, Jang Y. et al. [16] demonstrated that auraptene (AUR), a 7-geranyloxylated coumarin
isolated from citrus fruit, is able to counteract neurotoxin-induced reduction of mitochondrial respiration
and to inhibit reactive oxygen species (ROS) generation in SN4741 mouse embryonic substantia nigra
dopaminergic neuronal cell line. Moreover, they observed, in a MPTP-induced PD mouse model,
that AUR treatment improved movement deficits in association with an increase in the number of
dopaminergic neurons in the substantia nigra.
Chiroma S.M. et al. [17] investigated the neuroprotective effect of Centella asiatica (CA), a plant
from the family of Apiaceae, in a rat model of neurodegeneration induced by d-galactose/aluminum
chloride (d-gal/AlCl3). These authors previously observed that CA extract can attenuate cognitive
deficits in this model of neurodegeneration and can also prevent morphological aberrations in the
CA1 region of hippocampus [18]. In the paper published in this Special Issue, they demonstrated that
CA significantly increased the levels of protein phosphatase 2 and decreased the levels of glycogen
synthase kinase-3 beta. Moreover, CA extract also counteracted apoptosis as it increased the expression
of the Bcl-2 mRNA level.
Finally, Javed H. et al. [19] demonstrated the neuroprotective effect of thymol, a dietary
monoterpene phenol, in a rat model of PD. In particular, neurodegeneration was induced by rotenone
at a dose of 2.5 mg/kg body weight for four weeks. Thymol, co-administered to rotenone for four weeks
at a dose of 50 mg/kg body weight, significantly attenuated dopaminergic neuronal loss, oxidative
stress and inflammation suggesting a protective effect of thymol in rotenone-induced PD.
Along with research papers, different reviews are also presented in this Special Issue.
As previously underlined, proteostasis failure plays a crucial role in the context of ageing
and neurodegeneration. Therefore, natural products targeting the proteostasis elements emerge as
a promising neuroprotective therapeutic approach to prevent or ameliorate the progression of these
disorders. Cuanalo-Contreras K. et al. [20] focused on this aspect and revised the current knowledge
regarding the use of natural products as modulators of different components of the proteostasis
machinery to counteract neurodegeneration. The majority of natural modulators of the proteostasis
network are of plant-origin, however some compounds of marine-animal-origin are also emerging.
They concluded that further studies are required to understand the precise mechanism of action of
the natural proteostasis activators, their off-target effects and their in vivo bioavailability. In their
review, Cho B. et al. [21] focused on the effect on natural products on the proteostasis elements such
as ubiquitin-proteasome system and autophagy (mitophagy) in experimental PD models. Moreover,
in the same experimental models, they also revised the neuroprotective effects of natural products on
mitochondrial dysfunction, oxidative stress, and hormesis. They summarized the efforts to use natural
extracts as lead compounds for the design of novel pharmacological candidates for the treatment
of age-related PD. Finally, they addressed two main limitations in the use of natural compounds
in counteracting neurodegeneration: the differences of experimental design, such as the quality
of the extracts and the forms of dosage, of the studies and the unclear therapeutic mechanism of
natural compounds.
Taking into account these two limitations Di Paolo M. et al. [22] analyzed the ethical framework of
the potential clinical use of natural products to counteract neurodegeneration, with particular attention
paid to the principles of biomedical ethics. They concluded that natural products could represent
a great promise for the treatment of neurodegeneration, where traditional therapies, via synthetic
drugs, only act to alleviate symptoms. However, lack of knowledge on the efficacy and safety of
many natural products underscores the urgent need for further investigation to better characterize the
therapeutic mechanism of natural products in order to promote patient safety and ethical care.
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Park J.Y. et al. [23] revised the current research on the structural diversity, biosynthesis,
and pleiotropic neuronal functions of ascaroside (ascr) pheromones and their implications in animal
physiology. Pheromones are neuronal signals that stimulate conspecific individuals to react to
environmental stressors or stimuli. The authors also discuss the concentration and stage-dependent
pleiotropic neuronal functions of ascr pheromones. They suggest that in the future, translation of
the knowledge of nematode ascr pheromones to higher animals might be beneficial, as it has been
observed that ascr has some anti-inflammatory effects in mice.
Pervin M. et al. [24] discuss the function of (−)-epigallocatechin gallate (EGCG) and its microbial
ring-fission metabolites in the brain as neuroprotective agent. EGCG, the main green tea catechin,
is an ester of (−)-epigallocatechin (EGC) and gallic acid (GA). Despite the great number of studies on the
neuroprotective effects of green tea catechins against neurological disorders, it should take into account
that the concentration of EGCG in systemic circulation is very low and EGCG disappears within
several hours. EGCG undergoes extensive metabolism and recent studies suggest that metabolites
of EGCG may play an important role, alongside the beneficial activities of EGCG, in reducing
neurodegenerative diseases.
Barbalace M.C. et al. [25] focused on the effect of marine algae on neuroinflammation, one of the
main contributors to the onset and progression of neurodegenerative diseases. As pointed out by
Cuanalo-Contreras K. et al., marine organisms represent a vast source of natural compounds, and among
them, algae are an appreciated source of important bioactive components. Barbalace et al. revised the
numerous anti-inflammatory compounds that have been recently isolated from marine algae with
potential protective efficacy against neuroinflammation.
Polyphenols are among the most studied dietary molecules probably for their multiple and often
overlapping reported modes of action. Epidemiological studies suggest a strong association between
polyphenol consumption and reduced prevalence of various neurodegenerative diseases; however,
ambiguity still exists as to the significance of their influence on human health. Renaud J. and Martinoli
M.G. [26] analyzed the characteristics and functions of polyphenols that determine their potential
therapeutic actions in neurodegenerative disorders. In particular, they discuss the properties that may
influence the functionality and bioavailability of dietary polyphenols in the central nervous system
(CNS) with a particular focus on therapeutic applications and limitations.
Among polyphenols, curcumin, a component of Curcuma longa, is currently considered one of the
most effective nutritional antioxidants due to its activity in multiple antioxidant and anti-inflammatory
pathways involved in neurodegeneration. Mhillaj E. et al. [27] provides a summary of the main findings
involving the heme oxygenase/biliverdin reductase system as a valid target in mediating the potential
neuroprotective properties of curcumin. Moreover, they address the pharmacokinetic properties and
concerns about curcumin’s safety profile.
Maher P. [27] focused on a wide class of polyphenols, flavonoids. Among the huge number of
polyphenols, several epidemiological studies have specifically highlighted the potential beneficial
role of flavonoids to counteract neurodegeneration. In particular the author discusses the beneficial
effects of multiple flavonoids in different models of neurodegenerative diseases and identified common
mechanisms of action. As outlined by other authors of this Special Issue, the conclusions state
that further investigations should be carried out in order to use flavonoids in the treatment of
neurodegenerative diseases.
Infante-Garcia C. and Garcia-Alloza M. [28] reviewed natural compounds with a protective
activity against brain neurodegeneration in animal models of diabetes mellitus, taking into account
several therapeutic targets: inflammation and oxidative stress, vascular damage, neuronal loss or
cognitive impairment. Diabetic brain is characterized by micro and macrostructural changes, such as
neurovascular deterioration or neuroinflammation that lead to neurodegeneration and progressive
cognition dysfunction. The authors evidenced that natural compounds and extracts show antioxidant
and anti-inflammatory activities at a central level, as well as a relevant capacity to reduce vascular
damage, contributing altogether to limit neurodegeneration and cognitive derived alterations. In their
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conclusion the authors highlighted that natural products could contribute to expand therapeutic
options to treat or reduce central complications associated with diabetes mellitus.
Andrade S. et al. [29] focus their attention on a specific neurodegenerative disease, AD, and discuss
both the natural compounds already in clinical trial phase and other natural compounds with known
potentially beneficial effects in AD in a preclinical development stage. Regarding the preclinical
studies, only the most recent reported works have been considered. Clinical trials have demonstrated
that different compounds appear to be effective for AD therapy, on the contrary others have failed in
human trials. Natural compounds in earlier phases of research need further studies to uncover their
therapeutic potential for AD.
Berezowska M. et al. [21] reviewed the effects of vitamin D in multiple sclerosis on pathology
and symptoms. Based on specific criteria, they selected ten studies with a size ranging from 40 to
94 people and with a duration of the intervention from 12 to 96 weeks; all the studies compared the use
of vitamin D with a placebo or low dose vitamin D. One trial found a significant effect on Expanded
Disability Status Scale (EDSS) score, three demonstrated a significant change in serum cytokines level,
one found benefits in enhancing lesions and, interestingly, three studies reported no serious adverse
events in the use of vitamin D.
In conclusion, the papers published in this Special Issue, despite addressing different topics,
can be considered an important contribution to the knowledge of the neuroprotective effect of natural
products, and present a great deal of information related to both the benefits but also the limitations of
their use in counteracting neurodegeneration.
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